Key Insights

Highlights

Success Rate

100% trial completion (above average)

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 30/100

Termination Rate

0.0%

0 terminated out of 3 trials

Success Rate

100.0%

+13.5% vs benchmark

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 3 completed with results

Key Signals

100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
P 4 (2)

Trial Status

Completed3

Trial Success Rate

100.0%

Benchmark: 86.5%

Based on 3 completed trials

Clinical Trials (3)

Showing 3 of 3 trials
NCT06154408Not ApplicableCompleted

Evaluating the Impact of Omega-3 Fatty Acid Supplementation (Soloways™) on Lipid Profiles in Adults With PPARG Polymorphisms

NCT05661552Phase 4CompletedPrimary

Effect of Early Initiation of Evolocumab on Lipid Profiles Changes in Patients With ACS Undergoing PCI

NCT06333158Phase 4CompletedPrimary

Extracts of Amla, Walnut Leaf, Red Yeast Rice and Olive in Cardiovascular Prevention

Showing all 3 trials

Research Network

Activity Timeline